If you have been reading about TH9507 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or loose powder |
| Solubility | Freely soluble in water | Salt form dissolves readily in aqueous buffer |
| Storage (lyophilized) | 2 to 8 °C | Protect from light and moisture |
| Common purity method | Reversed-phase HPLC | Reported as peak-area percentage |
| Identity confirmation | Electrospray mass spectrometry | Measured mass compared with theoretical value |
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Nature Communications, 6, 7564. https://doi.org/10.1038/ncomms8564 J. Su, P. Wang, W. Zhou, M. Peydayesh, J. Zhou, T. Jin, F. Donat, C. Jin, L. Xia, K. Wang, F. Ren, P. Van der Meeren, F. Pelayo García de Arquer & R. Mezzenga (2024). Single-site iron-anchored amyloid hydrogels as catalytic platforms for alcohol detoxification. Nature Nanotechnology, 19(8), 1168–1177. https://doi.org/10.1038/s41565-024-01657-7 J. Zhou, S. Gowachirapant, C. Zeder, A. Wieczorek, J. Guth, I. Kutzli, S. Siol, F. von Meyenn, M. B. Zimmermann & R. Mezzenga (2025). Oat protein nanofibril–iron hybrids offer a stable, high-absorption iron delivery platform for iron fortification. Nature Food, 6, 1164–1175. https://doi.org/10.1038/s43016-025-01260-6 J. Adamcik & R. Mezzenga (2018). Amyloid polymorphism in the protein folding and aggregation energy landscape. Angewandte Chemie International Edition, 57(28), 8370–8382. https://doi.org/10.1002/anie.201713416 D. Xu, J. Zhou, W.L. Soon, I. Kutzli, A. Molière, S. Diedrich, M. Radiom, S. Handschin, B. Li, L. Li, S. J. Sturla, C. Y. Ewald, R. Mezzenga (2023). Food amyloid fibrils are safe nutrition ingredients based on in-vitro and in-vivo assessment. Nature Communications, 14(1), 6806. https://doi.org/10.1038/s41467-023-42486-x
primary The simplest, most commonly known, or canonical form of a chemical compound with multiple similar or isomeric forms. For example, in a primary alcohol, the carbon is bonded to a single substituent group (R1CH2OH), whereas a secondary alcohol is doubly substituted (R1R2CHOH) and a tertiary alcohol is triply substituted (R1R2R3COH).
This fostered the amassing of enormous economic and political power by a few prominent industrialists, largely through the formation of trusts and monopolies to prevent competition. This resulted in significant increases in economic inequality, slum conditions, and civil unrest, creating a fertile environment for labor unions to flourish and, to a more limited extent, socialist movements to emerge. This period eventually ended with the advent of the Progressive Era, which was characterized by significant economic, legislative and social reforms. Pro-American elements in Hawaii overthrew the Hawaiian monarchy; the islands were annexed in 1898. That same year, Puerto Rico, the Philippines, and Guam were ceded to the U.S. by Spain after the latter's defeat in the Spanish–American War. (The Philippines was granted full independence from the U.S. on July 4, 1946, following World War II. Puerto Rico and Guam have remained U.S. territories.) American Samoa was acquired by the United States in 1900 after the Second Samoan Civil War. The U.S. Virgin Islands were purchased from Denmark in 1917 after Danish voters approved the sale in a 1916 referendum.
Sources: en.wikipedia.org
== Research == Wadden’s research has focused on the behavioral and medical management of obesity. His early work on very low-calorie diets (VLCDs) included the first long-term trial of high-protein VLCDs, showing short-term efficacy but frequent weight regain, which underscored the need for long-term maintenance strategies. In the 1990s, he helped establish methods for evaluating commercial weight-loss programs, contributing to federal consumer-protection efforts. Beginning in the late 1990s, Wadden’s trials demonstrated that combining weight-loss medications with intensive lifestyle intervention (ILI) produced greater weight reduction than either approach alone, shaping clinical guidelines and drug trial designs. He also played a central role in research that supports the Centers for Medicare and Medicaid Services reimbursement of intensive behavioral therapy (IBT) for obesity. His studies showed that brief, protocol-driven IBT sessions delivered in primary care produced clinically meaningful weight loss. As a principal investigator on the NIH-funded Look AHEAD trial, Wadden helped show that ILI improved cardiometabolic risk factors, physical function, quality of life, and health-care costs in patients with type 2 diabetes, despite not reducing cardiovascular events. More recently, he has reported on glucagon-like peptide-1 (GLP-1) medications such as semaglutide and tirzepatide, which produce substantial weight loss and health benefits.
== Biology, medicine and chemistry == Code C08 Calcium channel blockers, in ATC (Anatomical Therapeutic Chemical Classification System) C08, Malignant neoplasm of other and unspecified major salivary glands ICD-10 code C8 complex, three proteins involved in the complement system (part of the immune system) Cervical spinal nerve 8 in human anatomy Carbon-8 (C-8 or 8C), an isotope of carbon An octyl-type hydrocarbon with eight carbon atoms like in a C8 bonded silica stationary phase column, a type of column used in reversed-phase chromatography Perfluorooctanoic acid (PFOA, known colloquially as C8), a ubiquitous chemical used in the production of PTFE
== External links == The MEROPS online database for peptidases and their inhibitors: S11.001 EC 3.4.16.4 Serine-Type+D-Ala-D-Ala+Carboxypeptidase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Criminal forensics === GC–MS can analyze the particles from a human body in order to help link a criminal to a crime. The analysis of fire debris using GC–MS is well established, and there is even an established American Society for Testing and Materials (ASTM) standard for fire debris analysis. GCMS/MS is especially useful here as samples often contain very complex matrices, and results used in court need to be highly accurate.
Sources: en.wikipedia.org
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.
Mass spectrometry serves as the primary identity check, since the measured mass must agree with the theoretical value for a 44-residue sequence. Chromatographic retention time and peptide mapping supply supporting evidence.
Certificates of analysis and independent testing tie a specific lot to specific measured results. Without that link, purity and identity claims rest on the supplier's own statement rather than on verifiable data.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.